Bivalirudin, blood loss, and graft patency in coronary artery bypass surgery

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 3, 2004, Pages 337-346

  Merry, Alan F ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anticoagulants; Bivalirudin; Blood loss; Heparin; Off pump coronary artery bypass surgery

Indexed keywords

ACETYLSALICYLIC ACID; ANCROD; ANTICOAGULANT AGENT; ARGATROBAN; DALTEPARIN; DANAPAROID; DESULFATOHIRUDIN; DIPYRIDAMOLE; EFEGATRAN; ENOXAPARIN; HEPARIN; HIRUDIN; HIRULOG; ILOPROST; INOGATRAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTAMINE; THROMBIN INHIBITOR; TIROFIBAN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CROSS ALLERGY; DRUG HYPERSENSITIVITY; GRAFT PATENCY; HUMAN; INFLAMMATION; OFF PUMP CORONARY SURGERY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS;

ANCROD; ANGIOGRAPHY; ANTICOAGULANTS; CHONDROITIN SULFATES; CORONARY ARTERY BYPASS; DERMATAN SULFATE; DRUG COMBINATIONS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARITIN SULFATE; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PROTAMINES; RECOMBINANT PROTEINS; REGIONAL BLOOD FLOW; SYNDROME; THROMBIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 3843052398     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-831046     Document Type: Review

References (67)

1. Merry A, Raudkivi P, Middleton N, et al. Bivalirudin versus heparin and protamine in off-pump coronary bypass surgery. Ann Thorac Surg 2004;77:925-931
2. Gibbon JHJ. The development of the heart-lung apparatus. Am J Surg 1978;135:608-619
3. Nunley RM, Lachiewicz PF. Mortality after total hip and knee arthroplasty in a medium-volume university practice. J Arthroplasty 2003;18:278-285
4. Charlesworth DC, Likosky DS, Marrin CA, et al. Development and validation of a prediction model for strokes after coronary artery bypass grafting. Ann Thorac Surg 2003;76: 436-443
5. Engoren MC, Habib RH, Zacharias A, et al. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 2002;74:1180-1186
6. Spiess BD. Blood transfusion: the silent epidemic. Ann Thorac Surg 2001;72:S1832-S1837
7. Spiess BD. Heparin: beyond an anticoagulant. In: Spiess BD, ed. The Relationship between Coagulation, Inflammation, and Endothelium. Baltimore, MD; Lippincott Williams & Wilkens; 2000:169-190
8. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997;95:1242-1246
9. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res 2002;106:V275-V284
10. Spiess BD. Transfusion and outcome in heart surgery. Ann Thorac Surg 2002;74:986-987
11. Williams RT, Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 2003;107:2307-2312
12. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335
13. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 1999;99: 2530-2536
14. Mattioli AV, Bonetti L, Sternieri S, Mattioli G. Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1-year follow-up. Ital Heart J 2000;1:39-42
15. Simoons ML. Investigators GI-A. Effect of glycoprotein IIb/ IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-1924
16. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 1998;80:292-297
17. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. Am J Cardiol 1998;82:12P-18P
18. Butterworth J, Lin YA, Prielipp RC, et al. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg 2002;74:1589-1595
19. Kimmel SE, Sekeres M, Berlin JA, Ellison N. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass. Anesth Analg 2002;94: 1402-1408
20. Physician's Desk Reference. Protamine; 2000
21. Frederiksen JW. Cardiopulmonary bypass in humans: bypassing unfractionated heparin. Ann Thorac Surg 2000;70:1434-1443
22. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698
23. Massonnet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986;16: 139-146
24. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96:182-187
25. Doherty DC, Ortel TL, de Bruijn N, Greenberg CS, Van Trigt P III. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass. Anesthesiology 1990; 73:562-565
26. Illig KA, Ouriel K. Ancrod: understanding the agent. Semin Vasc Surg 1996;9:303-314
27. Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31:1449-1459
28. Walls JT, Curtis JJ, Silver D, et al. Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition. Ann Thorac Surg 1992;53:787-791
29. Laster J, Elfrink R, Silver D. Reexposure to heparin of patients with heparin-associated antibodies. J Vasc Surg 1989; 9:677-682
30. Koster A, Kukucka M, Bach F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001;94:245-251
31. Koster A, Meyer O, Fischer T, et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg 2001;122:1254-1255
32. Pötzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia [letter]. N Engl J Med 2000;343:515
33. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 108:2062-2065
34. Nowak G, Bucha E. Prothrombin conversion intermediate effectively neutralizes toxic levels of hirudin. Thromb Res 1995;80:317-325
35. Koster A, Kuppe H, Hetzer R, et al. Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 1998;89:777-780
36. Fischer BE, Schlokat U, Himmelspach M, Dorner F. Binding of hirudin to meizothrombin. Protein Eng 1998;11:715-721
37. Koster A, Chew D, Grundel M, et al. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. Anesth Analg 2003;96:383-386
38. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997;23:503-516
39. Lubenow N, Selleng S, Wollert HG, et al. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg 2003;75:577-579
40. Edwards JT, Hamby JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003;75:1622-1624
41. Furukawa K, Ohteki H, Hirahara K, Narita Y, Koga S. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg 2001;122:1255-1256
42. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Therap 2002; 71:433-439
43. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 1993;69:157-163
44. White H. Hirulog, Early Reperfusion or Occlusion-2 Trial I: thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855-1863
45. Fuchs J, Cannon CP. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 1995;92:727-733
46. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/ non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Am Heart J 2002;143:229-234
47. Pötzsch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin clotting time. Thromb Haemost 1997;77:920-925
48. Despotis GJ, Hogue CW, Saleem R, et al. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg 2001;93:28-32
49. Pötzsch B, Hund S, Madlener K, Unkrig C, Müller-Berghaus G. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thromb Res 1997;86:373-383
50. Koster A, Despotis G, Gruendel M, et al. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. Anesth Analg 2002;95:26-30
51. Koster A, Kuppe H, Crystal GJ, Mertzlufft F. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin. Anesth Analg 2000;90:292-298
52. Cho L, Kottke-Marchant K, Lincoff AM, et al. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. Am J Cardiol 2003;91:1110-1113
53. Demir M, Iqbal O, Untch B, et al. Ecarin clotting time is sensitive to heparinoids: comparison of two different techniques. Clin Appl Thromb Hemost 2001;7:38-43
54. Pivalizza EG. Monitoring of hirudin therapy with the Thrombelastograph. J Clin Anesth 2002;14:456-458
55. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333:764-769
56. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-1629
57. Mariani MA, Gu YJ, Boonstra PW, et al. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? Ann Thorac Surg 1999;67:1370-1375
58. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302
59. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999;100: 2049-2053
60. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863
61. Puskas JD, Thourani VH, Marshall JJ, et al. Clinical outcomes, angiographic patency, and resource utilization in 200 consecutive off-pump coronary bypass patients. Ann Thorac Surg 2001;71:1477-1484
62. Angelini GD, Taylor FC, Reeves BC, Ascione R. Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHA-CAS 1 and 2): a pooled analysis of two randomised controlled trials. Lancet 2002;359:1194-1199
63. Zehr KJ, Handa N, Bonilla LF, Abel MD, Holmes DR Jr. Pitfalls and results of immediate angiography after off-pump coronary artery bypass grafting. Heart Surg Forum 2000;3: 293-299
64. Kim KB, Lim C, Lee C, et al. Off-pump coronary artery bypass may decrease the patency of saphenous vein grafts. Ann Thorac Surg 2001;72:S1033-S1037
65. Vasquez JC. Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. Ann Thorac Surg 2002; 74:2177-2179
66. Spiess BD, DeAnda A, McCarthy A, et al. Off-pump CABG in a patient with HITT anticoagulated with bivalirudin: a case report. Anesth Analg 2002;93:SCA70
67. Davis Z, Anderson R, Short D, Garber D, Valgiusti A. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg 2003;75:264-265